| From: |
|
G P Matthews - Medicines and Healthcare Products Regulatory Agency
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Trusts (England) - Medical Director
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
|
|
|
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Chief Executive
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Action category: |
|
Class 2: Action within 48 hours
|
| Title: |
|
DRUG ALERT CLASS 2, ACTION WITHIN 48 HOURS, SANDOZ LTD., Co-amoxiclav 125 mg/31.25 mg/5 ml Powder for Oral Suspension and Co-amoxiclav 250 mg/62.5 mg/5 ml Powder for Oral Suspension
|
| Broadcast content: |
|
Recall due to a potential packaging problem relating to poor seal which could potentially render the product ineffective.
Wholesalers and health care professionals:
Stop supplying the above noted batches of this product
Remaining stocks of the impacted batches should be quarantined and returned to your original supplier
Full details of the drug alert are included in the attached PDF file .Please forward to listed recipients. The information is also published on the MHRA website https://www.gov.uk/drug-device-alerts
|
| Cascade to: |
|
- #GP#
- #ACCIDENTEMERGENCY#
- #COMMUNITYPHARMACISTS#
- #DISPENSING GP#
- #HospitalPharmacy#
|